GlassScriptPhysician profile
Hima Ammana
NPI 1902250343
$8,558.47
in general payments reported to CMS, 2019-2025
33 companies · $1,928 in 2025
The $1,928 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $759 · 2022: $1,840 · 2023: $2,244 · 2024: $1,787 · 2025: $1,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,959 · Education: $0.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,958.55 |
| Education | $0.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,407.00 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $826.63 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $804.50 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $704.13 | 2021-2025 | |
| Radius Health, INC. | $464.53 | 2023-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $395.07 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $369.12 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.43 | 2021-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $271.26 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Corcept Therapeutics | $267.38 | 2021-2025 | Korlym |
| Beta Bionics, INC. | $265.63 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Medtronic, INC. | $222.55 | 2024-2025 | Simplera Sensor, Minimed 780g |
| Amneal Pharmaceuticals LLC | $222.10 | 2023-2025 | Unithroid |
| Amgen INC. | $220.49 | 2021-2025 | Tepezza, Evenity, Prolia |
| Mannkind Corporation | $201.56 | 2022-2025 | Afrezza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $192.88 | 2023-2025 | |
| Ibsa Pharma INC. | $186.40 | 2021-2025 | Tirosint, Licart, Flector |
| Antares Pharma, INC. | $165.10 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Astrazeneca Pharmaceuticals LP | $158.56 | 2021-2022 | |
| Abbvie INC. | $158.19 | 2021-2025 | Synthroid |
| Insulet Corporation | $141.35 | 2021-2025 | Omnipod |
| Amarin Pharma, INC. | $108.80 | 2021-2022 | |
| Amryt Pharma Holdings LTD | $104.33 | 2023 | Mycapssa |
| Alexion Pharmaceuticals, INC. | $85.26 | 2023-2024 | Strensiq |
| Tandem Diabetes Care, INC. | $83.09 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $59.31 | 2025 | Isturisa |
| Regeneron Healthcare Solutions, INC. | $47.26 | 2025 | Evkeeza |
| Chiesi USA, INC. | $44.52 | 2025 | Mycapssa |
| Esperion Therapeutics, INC. | $25.98 | 2023 | Nexletol |
| Kyowa Kirin, INC. | $22.19 | 2023 | Crysvita |
| Glaxosmithkline, LLC. | $19.75 | 2025 | Shingrix, Arexvy |
| Pfizer INC. | $15.78 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $15.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hima Ammana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.